PDF(Sci-hub)
Abstract：
To assess the clinical features, diagnosis, and treatment of bone sarcoidosis in the United States.
Patients with bone sarcoidosis were identified and matched to sarcoidosis patients based on race, gender, and age. Detailed characteristics were obtained by medical record review.
A total of 64 patients with bone sarcoidosis were enrolled in this study. The female:male ratio was 1.46:1 and the white:black ratio was 3:1. Thirty-eight (59.4%) of 64 patients had bone symptoms. Compared to matched cases, bone sarcoidosis patients have more multi-organ involvement and higher incidence with liver, spleen, and extrathoracic lymph node involvement than controls (P < 0.05). Spine was the most commonly affected bone in 44 (68.8%) of patients, followed by pelvis (35.9%), and hands (15.6%). MRI and PET/CT scan was the common imaging technology, which performed in 36 patients and 32 patients, respectively, and with 97.2% and 93.8% positive bone uptake. Laboratory test indicated anemia was more common in bone sarcoidosis group than controls (P = 0.044). Infliximab was more commonly used in bone sarcoidosis patients than controls (P = 0.009).
Bone sarcoidosis was associated with multi-organs affection, and high frequency of liver, spleen, or extrathoracic lymph node involvement. Infliximab should be considered in those patients with aggressive and refractory bone sarcoidosis.
Patients with bone sarcoidosis were identified and matched to sarcoidosis patients based on race, gender, and age. Detailed characteristics were obtained by medical record review.
A total of 64 patients with bone sarcoidosis were enrolled in this study. The female:male ratio was 1.46:1 and the white:black ratio was 3:1. Thirty-eight (59.4%) of 64 patients had bone symptoms. Compared to matched cases, bone sarcoidosis patients have more multi-organ involvement and higher incidence with liver, spleen, and extrathoracic lymph node involvement than controls (P < 0.05). Spine was the most commonly affected bone in 44 (68.8%) of patients, followed by pelvis (35.9%), and hands (15.6%). MRI and PET/CT scan was the common imaging technology, which performed in 36 patients and 32 patients, respectively, and with 97.2% and 93.8% positive bone uptake. Laboratory test indicated anemia was more common in bone sarcoidosis group than controls (P = 0.044). Infliximab was more commonly used in bone sarcoidosis patients than controls (P = 0.009).
Bone sarcoidosis was associated with multi-organs affection, and high frequency of liver, spleen, or extrathoracic lymph node involvement. Infliximab should be considered in those patients with aggressive and refractory bone sarcoidosis.
摘要：
为了评估临床特征，诊断,以及在美国的骨结节病的治疗。
根据种族确定骨结节病患者并与结节病患者相匹配，性别,和年龄。通过病历审查获得了详细的特征。
本研究共纳入64例骨结节病患者。女性:男性比例为1.46:1,白色:黑色比例为3:1。64例患者中有38例（59.4％）出现骨症状。与匹配的病例相比，骨结节病患者多器官受累，肝脏发病率较高，脾,脾胸外淋巴结受累优于对照组(P<0.05)。脊柱是44例（68.8%）患者中最常见的骨，其次是骨盆(35.9%)，和手（15.6%）。MRI和PET/CT扫描是常用的成像技术,在36名患者和32名患者中进行，分别,骨摄取阳性率为97.2%和93.8%。实验室检查提示骨结节病组贫血发生率高于对照组(P=0.044)。英夫利昔单抗更常用于骨结节病患者（P=0.009）。
骨结节病与多器官病变有关，和高频率的肝脏，脾,脾或胸外淋巴结受累.对于侵袭性和难治性骨结节病患者，应考虑使用英夫利昔单抗。
根据种族确定骨结节病患者并与结节病患者相匹配，性别,和年龄。通过病历审查获得了详细的特征。
本研究共纳入64例骨结节病患者。女性:男性比例为1.46:1,白色:黑色比例为3:1。64例患者中有38例（59.4％）出现骨症状。与匹配的病例相比，骨结节病患者多器官受累，肝脏发病率较高，脾,脾胸外淋巴结受累优于对照组(P<0.05)。脊柱是44例（68.8%）患者中最常见的骨，其次是骨盆(35.9%)，和手（15.6%）。MRI和PET/CT扫描是常用的成像技术,在36名患者和32名患者中进行，分别,骨摄取阳性率为97.2%和93.8%。实验室检查提示骨结节病组贫血发生率高于对照组(P=0.044)。英夫利昔单抗更常用于骨结节病患者（P=0.009）。
骨结节病与多器官病变有关，和高频率的肝脏，脾,脾或胸外淋巴结受累.对于侵袭性和难治性骨结节病患者，应考虑使用英夫利昔单抗。
